Literature DB >> 307998

Metabolism of intact and desialylated alpha 1-antitrypsin.

E A Jones, J Vergalla, C J Steer, P R Bradley-Moore, J M Vierling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 307998     DOI： 10.1042/cs0550139

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN： 0301-0538


× No keyword cloud information.
  10 in total

1.  GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes.

Authors:  Kathleen Dungan; Philip Binkley; Kwame Osei
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

2.  Selective hepatic uptake of human beta-hexosaminidase A by a specific glycoprotein recognition system on sinusoidal cells.

Authors:  C J Steer; J W Kusiak; R O Brady; E A Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

3.  Profiles of acute-phase reactants and clinical significance of alpha 2-macroglobulin in acute hepatitis B.

Authors:  J Van Gool
Journal:  Inflammation       Date:  1983-09       Impact factor: 4.092

4.  A model of decreased functional alpha-1-proteinase inhibitor. Pulmonary pathology of dogs exposed to chloramine T.

Authors:  W R Abrams; A B Cohen; V V Damiano; A Eliraz; P Kimbel; D R Meranze; G Weinbaum
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

5.  Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.

Authors:  Eeva Piitulainen; Elisabeth Bernspång; Sven Björkman; Erik Berntorp
Journal:  Eur J Clin Pharmacol       Date:  2003-05-01       Impact factor: 2.953

6.  Change in alpha 1-antitrypsin phenotype after orthotopic liver transplant.

Authors:  R van Furth; J A Kramps; A B van der Putten; R A Krom; C H Gips
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

7.  Danazol-induced augmentation of serum alpha 1-antitrypsin levels in individuals with marked deficiency of this antiprotease.

Authors:  J E Gadek; J D Fulmer; J A Gelfand; M M Frank; T L Petty; R G Crystal
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

Review 8.  Alpha 1-antitrypsin. Hope on the horizon for emphysema sufferers?

Authors:  M Schwaiblmair; C Vogelmeier
Journal:  Drugs Aging       Date:  1998-06       Impact factor: 3.923

9.  Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects.

Authors:  J E Gadek; H G Klein; P V Holland; R G Crystal
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 10.  The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals.

Authors:  Danielle M Dunlea; Laura T Fee; Thomas McEnery; Noel G McElvaney; Emer P Reeves
Journal:  J Inflamm Res       Date:  2018-03-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.